(SNPX) – Synaptogenix’s Alzheimer’s Candidate Displays Signs Of Safety In Mid-Stage Study

  • Synaptogenix Inc (NASDAQ: SNPX) has announced an update on its ongoing National Institutes of Health (NIH) sponsored Phase 2b trial of Bryostatin-1 for moderately severe Alzheimer’s disease (AD).
  • To date, the Company has dosed 58 of its target 100 patients.
  • Additionally, the independent Data Safety Monitoring Board (DSMB) confirmed that 40 advanced AD patients had been dosed with Bryostatin without any significant safety issues.
  • Price Action: SNOX shares are up 0.57% at $7.05 during the market session on the last check Wednesday.

Get Stock Market Insights, Technical Analysis, Live Market Data, ratings, insider trades
Shopping cart